self help twist
initi equal-weight
expect consensu revis ep oper
margin estim sartoriu stake
valuat howev look price multipl
near histor high initi equal-weight pt
great stori cheap share vs year reflect
organ growth acceler vs margin expans
year year flattish margin increas valu
stake common prefer sartorius/srt german
bioprocess/lab product instrument manufactur fundament
sound driver price appreci cours year consensu
ep alreadi higher stake becom
increasingli appreci investor share year
multipl expans valuat give full valu stake
liquid discount expect ep track consensu
yet struggl find upsid stock current level pt
impli upsid spite assumpt lower yield target
base busi coverag averag reflect faster
growth investor may see greater upsid tactic share look cheaper
ev/ebitda captur higher capital-expenditure load sale vs
peer closer ex-srt trade discount peer
ev/ebitda basi trade premium yield
premium core tool name
oper effici continu drive oper margin
consensu past five year invest erp system
complet dilut acquisit time ebit margin fell
project complet identifi cost save
driven fade erp implement spend ration
target specif initi achiev addit
save model organ ebit margin expans exclud
specifi program erp suppli chain save etc in-lin
histor trend sinc margin estim averag higher
vs consensu spite model stabl underli trend put
simpli believ consensu either assum announc save program
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
succeed assum underli margin trend break long-term
see path ebit margin rel current consid
margin under-optim rel peer similar instrument mix
srt/sartoriu stake long term posit present valuat
challeng estim stake enterpris valu
own roughli famili trust hold control
interest outstand vote share aim ultim take full control
compani control famili trust laps roughli year
see favor dynam market play see pharma
driver price-to-earnings multipl eu index all-tim high
present key point uncertainti share pt assum
chang valu stake rel current market valu
revenu growth hit high end guidanc end market life
scienc clinic diagnost instruments/consumables/servic grow
averag forecast organ growth high
end medium term guidanc improv life scienc fund pharma
spend sustain driver see strong fundament growth
ddpcr compris roughli sale droplet digit pcr ddpcr
dna analysis/detect method use water-oil emuls droplet
map risk see valu sourc uncertainti
necessarili upside/downsid risk upsid strong pharma/academ
fund could drive end market growth view new product
blood typing/screen could take share expect ddpcr uptak
could acceler singl cell applic cost ration effort could
track ahead plan commerci structur chang could drive greater share
gain downsid risk forecast includ less robust expect cost
save erp implement competitive/pr pressur clinic
diagnost market growth deceler ddpcr clinic uptak slower
expect sequenc technolog take share becom cheaper
valuat build summari valu use yield-bas methodolog
appli target yield base busi lower yield
improv significantli work capit margin expans improv
erp implement addit base busi add market
valu stake sartoriu ev calcul estim
worth pt impli ep in-lin ntm price-to-earnings
multipl consensu estim averag ntm price-to-earnings
multipl believ inflat consensu estim lag cost
bull case ep
bull case ep
sustain ddpcr growth better expect diagnost growth
lead organ growth erp save prove robust expect
lead ebit margin expans tax rate improv better
expect stronger profit multipl expand ep
current multipl closer peak histor level ep grow
y/i valuat stack also consid bio invest sartoriu
market valu own common share estim
prefer share sartoriu add addit
fcfi base busi impli base case ep
fcfi base busi impli base case ep
strong ddpcr growth lsd diagnost growth lead organ
growth erp save gener y/i ebit margin expans tax rate
improv move headquart lower-cost jurisdict
price target base yield mid estim
impli ep multipl in-lin current ntm level ep grow
y/i valuat stack also consid bio invest
sartoriu market valu own common share
estim prefer share sartoriu add addit
bio ev
bear case ep
bear case ep
teen ddpcr growth flat diagnost growth lead organ
growth erp implement success plan lead
ebit margin expans tax rate increas due advers tax
plan multipl contract ep current multipl
in-lin averag ep grow y/i valuat
stack also consid invest sartoriu market valu own
common share estim prefer share
sartoriu add addit bio ev
potenti above-p margin
expans attract larg priced-in
view think deliv
ebit margin expans
global sap roll-out
gener suppli chain procur
save see case lsd-msd organ
growth fail see materi upsid
current stock level even account
sartoriu asset market valu
model higher interest incom
proxi capit deploy
margin expans
growth us
risk achiev price
upsid risk includ cost save
oper leverag prove robust
competitive/pr posit defens
expect clinic diagnost market
iii ddpcr penetr clinic
market exce growth
downsid risk includ cost save
materi erp implement
europ challeng lead addit
invest slower margin expans ii
competitive/pr pressur intensifi
clinic diagnost market iii ddpcr
growth deceler competit enter
field clinic uptak slower
transform reach inflect point bio-rad global
diversifi manufactur life scienc clinic diagnost instrument
consumables/reag software/servic last decad begun
modern transform commerci infrastructur family-own
busi sizabl multi-national corpor implement global erp system
central manufactur commerci oper view enter
multi-year period consist result revenu front see acceler
life scienc deceler clinic diagnost drive forecast
organ growth stronger normal basi trail quarter
stack vs trend analysi suggest expand organ ebit margin
consist compani trend sinc put togeth appli
target yield base busi also ad market valu
stake sartoriu estim even consid valu stake
above-consensu estim abl find upsid stock
initi ew pt
stock cheap context import stock surg year
part function higher estim consensu ep ytd also function
sartoriu own share discuss stock ytd
one highest ntm p/e coverag flag
rel ntm price-to-earnings vs tool peer actual cut ytd past
month go forward think upward revis consensu estim like
though pt assum bit multipl contract compar peer
growth vs yield ex-srt basi look appropri valu exhibit
look significantli cheaper ev/ebitda basi flag ebitda
consid higher capital-expenditure load sale vs peer tax rate
note sartoriu current valu obtain use thomson reuter market cap data common/pref
share multipli current/pref ownership stake sum total
exhibit rel price-to-earnings premium significantli reduc
past month though still averag
exhibit growth expect bit stronger peer
averag valuat attract consid ex-srt
exhibit stake valu market account
pt note histor data repres ownership
note sartoriu current valu obtain use thomson reuter market cap data common/pref
share multipli current/pref ownership stake sum total
price-to-earnings vs eu
ntm rel price-to-earnings vs eu
exhibit ev/ebitda valuat attract ex-srt
valuat appear cheaper ebitda metric vs
high capital-expenditure capital-expenditure margin tax rate captur
ebitda
sartoriu trade peak valuat increasingli larg factor ev
indic stake common prefer sartorius/srt though
control oper estim stake worth
ev thu import consid valuat context invest
sartoriu current trade rel ntm premium vs eu
three-year histor averag ten-year histor
averag de-rat rel multipl vs eu three-year
averag would impli declin pt present data indic
degre uncertainti embed valuat valuat
control pt assum chang valu stake rel
averag consensu ep estim sale
estim averag consensu model
comp-adjust organ growth acceler ex-ddpcr vs trail trend
think robust base life scienc growth sustain still model
msd-hsd momentum sale estim could go higher cell biolog food
safeti process media growth prove sustain ebit margin estim
averag higher consensu organ basi appear
consensu call y/i deceler margin expans vs trend
closer y/i expans model y/i organ margin expans
larg consist trend overal ep estim
consensu given higher margin assumpt
exhibit invest worth market cap
market cap
exhibit consider street ep
given higher ebit margin estim though
understand margin bridg histor spent
erp program go forward erp program expect drive signific save
better effici purchasing/manufacturing/logist manag break
erp cost bucket follow
cost includ profession contractor consult hire consult
project ii duplic headcount relat new services/warehous iii cost
relat new system implement iv cost relat reorgan
busi function structur division one establish
new european headquart vi increas regulatori complianc program
vii expens relat project
suppli chain save close distribut center plan close
year addit compani intend close redund commerci
offic locat final plan move manufactur
asia factori expect save move million
procur save leverag new function organ obtain
signific price deliveri concess manag target save
benefit continu
sg leverag erp contribut increas visibl improv inventori
level servic reduc scrap lower project overhead manag note
increment erp spend fall y/i headcount reduct
save drive save per year start
margin build demand organ basi detail decomposit
margin consid rang factor last five year includ fx
acquisit divestitur erp spend cost save forecast
organ margin expans compar similar trail trend sinc
model organ increment margin vs organ increment
exhibit ms bridg show organ margin
expans
exhibit expect organ margin expans
mse average organ ebit margin exp bp
includ fx acquisition/divestitur impact erp spending/sav cost relat erp
think two busi track differ direct go forward life
scienc momentum given healthi dd growth ddpcr well acceler
research/pharma budget life scienc sale though estim base life
scienc busi ex-ddpcr grow lsd compound-annual-growth-rate see clinic diagnost
busi structur challeng given competit pressur market
well price pressur driven lab consolid model comp-adjust
acceler life scienc deceler diagnost arriv organ
growth forecast manag guidanc constant currenc
growth model acceler life scienc trail organ compound-annual-growth-rate
forward compound-annual-growth-rate clinic diagnost model deceler
trail organ compound-annual-growth-rate forward compound-annual-growth-rate
tool end market fundament strong longer call broad-
base acceler across end market see strong fundament
exhibit estim tool compani end market aggreg growth
risk upsid downsid see valu sourc
uncertainti necessarili upside/downsid risk upsid strong
pharma/academ fund could drive end market growth view new
product blood typing/screen could take share expect ddpcr
uptak could acceler singl cell applic cost ration effort could
track ahead plan commerci structur chang could drive greater share gain
downsid risk forecast includ less robust expect cost save erp
implement competitive/pr pressur clinic diagnost market growth
deceler ddpcr clinic uptak slower expect sequenc
technolog take share becom cheaper
execut summari think expand ebit margin next four
year impli organ margin expans given program cost save
benchmark instrument mix support analysi
margin target look ambiti compani histori benchmark suggest
reach ebit margin current lowest coverag
univers averag investor day manag laid plan
ebitda margin expans next three year
broke compon oper profit arriv organ margin
better assess aggress manag target note follow
adjust save termin gnubio effort
drop ebit balanc reinvest high-growth area like digit pcr ii
ration distribution/commerci offic site world-wide
save procur initi next three year iii elimin
erp repres save total model call averag
organ ebit margin expans in-lin compani
histor trend sinc believ abl leverag erp model drive
signific gross margin improv sg leverag note upsid
estim stronger oper leverag expens reduct
exhibit manag ebitda margin target call
ebitda margin expans three year
exhibit forecast ebit margin expans
shutdown save procur save
benchmark analysi suggest goal reach look tool
compani get sens potenti margin trajectori agil
seri cost save program abl averag organ
ebit margin expans per year dhr/pki abl averag without
program analysi suggest manag target within reach
adjust ebit margin would still lag peer averag
agil gener four consecut year organ ebit margin
expans gener cost save nmr market exit
agil agil program logistics/cost save program
saw organ ebit margin expans driven
closur product line divestitur footprint consolid outsourc
dhr/pki similar instrument mix averag
organ margin expans past three year though neither engag
margin expans weak organ basi margin far
optim went back past five year better assess organ margin
trend adjust item currenc headwind acquisitions/divestitur
erp one-tim item estim adjust ebit margin
report margin expans neg sinc
estim organ margin expans one
lowest level tool coverag
fx fx headwind drop oper profit accord
manag estim fx drag ebit past six
 acquisit gener dilut oper profit estim
quantalif headwind ebit serotec
headwind propel/raind headwind
erp spend year sinc cost significantli decreas
go zero accord manag
exhibit seen organ ebit margin
exhibit margin look far optim compar
instrument mix peer
revenu instrument
significantli under-perform expect margin look
instrument mix sale come instrument yet least six tool
compani higher instrument mix higher margin underli
margin profil sub-optim cash convers cycl day third highest tool
driven highest inventori day well second highest opex load tool
erp implement abl lower inventori level reduc
cost improv servic well significantli lower sg current
highest sg tool vs peer averag manag also target
gross margin improv move manufactur lower cost region
purchas consolid smaller logist footprint
erp preced suggest implement alway seamless spoke morgan
stanley counterpart europ cover sap se sap cover adam wood
compani select erp implement understand compani
fare follow sap system implement colleagu note
compani nestl nesn cover eileen khoo colgat cl cover
dara mohsenian publicli state sap driven cost save ebit margin
expans nestl state growth program aid sap given us
last sever year million million pre-tax annual
save recent compani cite save relat sap
technolog said colleagu note compani write off
hundr million dollar dedic year unexpectedli complex sap
implement well issu larg profit warn either system hasnt
work theyv miss rais profit expect critic program success
manag implement
repres risk valuat
execut summari think valuat alreadi captur margin expans
potenti well market valu sartoriu cover invest
stock look fulli price assess valuat use tradit fcf-base
methodolog give credit invest sartoriu share
estim market valu appli target yield arriv
pt upsid current stock level think market fulli price
margin expans potenti invest current trade
premium tool peer though flag rel ntm price-to-earnings vs tool peer
actual cut ytd past month consensu
estim need go higher think multipl expans like
exhibit invest worth market cap
market cap
note sartoriu current valu obtain use thomson reuter market cap data common/pref
share multipli current/pref ownership stake sum total
valuat cheaper invest consid yield
signific premium tool peer howev consid invest
yield closer make valuat appear in-lin addit
trade ev/ebitda premium vs core tool though note
would trade ev/ebitda premium closer exclud invest
said look significantli cheaper ev/ebitda basi flag
ebitda consid higher capital-expenditure load sale vs peer tax rate
exhibit growth expect bit stronger peer
averag valuat attract consid ex-srt
exhibit ev/ebitda valuat attract ex-srt
valuat appear cheaper ebitda metric vs
high capital-expenditure capital-expenditure margin tax rate captur
ebitda
exhibit price-to-earnings valuat appear attract ex-srt
note price-to-earnings ex- obtain subtract net debt market cap ownership total ev
includ ownership arriv stand-alon market cap
understand sartoriu invest bio-rad own common prefer
share sartoriu ag german bioprocess/lab product instrument
manufactur major vote share held sartoriu famili
trust famili member control oper
estim own common share prefer share
total invest market valu own share sartoriu
year manag indic sartoriu strateg invest
may act year think critic valu exclud
sartoriu invest get sens base busi trade
comment sartoriu recent analyst day
recent sartoriu famili trust sartoriu famili member hold
control interest outstand vote share
repres designe sartoriu board director
abil exercis signific influenc oper financi polici
analyst day one thing put chart
exclud project invest sartoriu
mani know longtim owner prefer share
vote share import invest us one view
long-term strateg
note knowledg potenti deal manag comment
upcom transact
growth strong despit lower convers peer expect convers
improv go forward convers much lower peer in-part
function higher capital-expenditure larg work capit drag said go forward
think convers improv dramat work capit improv
erp implement see convers increas histor
next four year think make sens valu use fcf-base
ev approach earn properli captur underli improv
oper valu sartoriu asset
exhibit lowest convers net incom
coverag driven higher capital-expenditure larg work capit
drag
exhibit convers lower recent year
expect return
valuat elev rel histori sartoriu current trade
rel ntm premium vs eu three-year histor averag
ten-year histor averag de-rat rel multipl
vs eu three-year averag would impli market cap
would impli stake declin therebi impli
pt lower current pt
price-to-earnings vs eu
ntm rel price-to-earnings vs eu
organ growth compound-annual-growth-rate unlik exceed
execut summari believ life scienc histor grower acceler
organ growth given strong dd growth ddpcr estim life
scienc revenu believ clinic diagnost histor grower
deceler organ growth given price pressur lab consolid
pama though new product introduct help off-set slow overal see
revenu acceler though manag
guidanc constant currenc growth
normal growth trend stabl assess organ growth trail two
quarter two year stack smooth quarter quarter volatil report
histor grown organ estim conserv assum
grow basi stabl trail three-year compound-annual-growth-rate
exhibit normal growth trend estim call acceler
competit landscap present challeng
life scienc compet larg tool compani
kgaa clinic diagnost compet tmo/dhr addit
diagnost compani biomerieux diasorin
touch point critic accord manag effect abl compet
larger compani offer superior custom support servic technic
expertis feel custom primarili look best technolog
market follow price give advantag said price pressur
competit dynam real threat yearli headwind revenu growth
expert dilig suggest lab see need bioplex spoke
diagnost expert evalu instrument compar competitor
product expert note bioplex system uniqu five year ago
compani roch cover siemen healthin shlg cover
michael jungl abbott cover david lewi caught better
assay fourth gener hiv test autom system thu reimburs
pressur increas lab look effici space/spend
incentiv purchas separ instrument line
competitor commentari suggest overal blood donation/transfus market
challeng grf point dd growth blood type vs
spoke medic devic get better understand blood market
well review transcript present cover
david lewi grifol grf cover david lewi dilig suggest compani
becom effici blood collect caus pressur supplier
consum market dilig expert addit indic blood
screen market becom concentr put cost pressur compani
confer blood market aggreg us
everyon meaning challeng probabl still fairli earli
least decad probabl closer decad long systemat declin
rate transfus
analyst day like like walk talk littl bit
market see today continu see blood util
declin north america signific recent past
exhibit compet larger tool name dhr/tmo well sever
competitor segment
manag organ growth target realist histor grown
organ revenu though past five year averag organ
growth investor day manag laid detail bridg
constant currenc growth compon bridg includ price
competit geograph expans new product
price competit price manag point european lab
consolid drive pressur investor day said europ us
come difficult period aw lot consolid franc
european lab seen littl bit rebound price pressur
also driven govern tender polici govern look save
also note blood viru busi declin year row
geograph expans expand us refer lab market first
time follow sign labcorp deal place blood type
instrument lab plan expand blood type busi china well
diabet monitor asia continu grow exposur asia
new product introduc new product cell sort digit pcr
qualiti control market compani expect growth new
exhibit manag long-term constant currenc growth target
exhibit diagnost exposur tool peer
exhibit us/eu exposur tool peer less
execut summari droplet digit pcr continu grow
penetr fast grow liquid biopsi categori life scienc overal
acceler given strength ddpcr stabil process media end market
strength driven pharma/academ market overal model stack
acceler though roughli stabl ex-ddpcr basi product funnel look
limit life scienc compar clinic diagnost suggest
depend ddpcr end market growth
droplet digit pcr ddpcr method perform digit pcr base
water-oil emuls droplet technolog sampl fraction droplet
pcr amplif templat molecul occur individu droplet
ddpcr allow research studi tumor variation/evolut clinic
ddpcr use monitor drug resist prevent overtreat
ddpcr applic liquid biopsi rapidli grow
mani potenti applic ddpcr manag call sampl prep
liquid biopsi two high-growth target area ddpcr think
target rna-seq whole genom sequenc resequenc
estim sampl prep product project market
grow compound-annual-growth-rate current develop second-gener
single-cel product liquid biopsi anoth fast grow market adopt
ddpcr target applic earli detect screen therapi guidanc
diagnosi residu diseas monitor estim
driven compound-annual-growth-rate
exhibit analysi suggest legaci life scienc product
grow lsd ddpcr grow healthi mid-teen pace
step clinic current custom
ddpcr research user primarili oncolog research though
pharma liquid biopsi user grow attempt
penetr clinic market next step ddpcr
product compani develop ce-ivd mark system
europ well submit ddpcr platform liquid
biopsi test blood cancer fda custom also
express interest put lab develop test
applic platform respons consid
licens third-parti kit develop put content platform
worth assum ddpcr busi grow ddpcr
contribut overal compani growth accord manag
ddpcr system global revenu grow growth
driven expand custom base new applic use
exhibit digit pcr weight toward research user
exhibit ddpcr sever advantag come
detect
costli longer time
process analyz
greater sensit
target set known
cost-effect rapid
ratio mutant wt
mutant wt copi
exhibit manag expect ddpcr solut liquid biopsi
market
exhibit expect ddpcr revenu grow compound-annual-growth-rate
inclus single-cel applic
exhibit market posit thermal cycler
partit nucleic acid sampl thousand
nanoliter-s droplet pcr amplif
carri within droplet
suspens array system offer reliabl
multiplex assay solut permit analysi
biomolecul singl sampl
break life scienc outlook pharma acceler doubl
digit growth look less like beyond tougher comp given process order trend
lighter forecast flattish fda approv optic strong easi comp
part due vc fund upsid risk lead indic concern
china/india consider academ hold strong trend recent
recoveri look sustain global synchron given fund commit
see strong fundament
saw strength across busi serv custom
base rang bioproduct excel chroma mass spec clinic
trial logist research safeti channel
academ fund good realli see dramat
pocket weak fact rel last number year strong
mid-single-digit growth actual realli nice spot domest
exhibit life scienc custom research/biopharma
see market growth acceler
exhibit pharma lab spend expect acceler
exhibit academ lab budget expect declin
exhibit fund disburs nih research
institut acceler june basi
note april data subject revis
custom stock led strong growth turn led larg declin
driven custom destock note market improv sinc driven
biolog manufactur manag see develop phase area
strongest growth prospect think three-year normal growth compound-annual-growth-rate
process media hsd
execut summari clinic diagnost model roughli stabl growth overal
competitive/pr pressur result pama implement lab
consolid somewhat off-set new product introduct labcorp blood
type deal bioplex autoimmun multiplex system help off-set
lab consolid go away
europ challeng european diagnost busi declin
quarter driven consolid clinic transfus lab
europ particularli franc drove price pressur clinic lab market
franc highli fragment top four oper estim market share
market paid reimburs french social
secur system remain account out-of-pocket spend
privat medic insur introduc blood type screen
instrument small medium size transfus lab help curb share loss
europ manag expect europ growth driver time soon
us next note dilig lab consolid like
downstream result pama note continu rate pressur could forc smaller
refer lab hospit lab close divert increas volum larg refer
lab abl perform assay lower price point manag note histor
lab oper squeez vendor face price pressur
given challeng europ result lab consolid would cautiou
us market pama rate implement
exhibit hospit capital-expenditure diagnost lab equip growth still
elev per survey
y/i chang hospit capit expenditur
y/i chang diagnost lab equip budget
data track stronger manag sentiment would
suggest despit caution manag regard
potenti pressur pama implement medic
broadli posit hospit utilization/capex outlook
head notabl take-away
acceler diagnost lab equip budget growth
y/i spite tougher y/i comp suggest revers
slowdown report global ivd revenu
result due core lab slowdown rais
concern aca/pama uncertainti impact custom hardwar
spend survey suggest concern overblown consist
commentari pama pressur hospit lab would like immateri
impact valid view pama limit impact tool name
total revenu exposur diversifi given reagent rental
see de-risk pama
player blood type market instal base
system late introduc blood type system us market
instrument throughput blood type busi
histor european-domin due restrict enter us market
restrict lift posit north america largest
blood bank market world recent sign multi-year labcorp agreement
place instrument give exposur us refer lab market
first time labcorp repres largest custom manag
expect reagent flow ramp see competit
pressur horizon blood type expect soon player
market said recent survey hospital/cor lab found hospit
signific opportun reduc blood util studi shown
blood transfus unnecessari avoid
fastest grow busi within clinic diagnost
autoimmun featur bioplex fulli
autom random-access multiplex system market
sold place bioplex system last two
year averag previou year manag think
go player market
system assay begin penetr
mid-volum lab addit bioplex attach
larger autom track system high volum test
custom also begin use instrument
infecti diseas test world first fifth-gener
hiv test recent receiv approv syphili test
exhibit estim player blood type
exhibit bioplex instal base test menu
exhibit market posit qualiti control blood
type diabet monitor market
measur glycat hemoglobin diabet
autom routin blood type screen
test procedur patient donor
fulli autom random access system blood
type screen
system offer full autom walk-away
reliabl allow laboratori effici
manag blood test workload
growth profil volatil grow much fall
gener growth per share flat past year
convert adjust net incom lowest
convers tool vs peer averag convers revenu
similarli peer lowest among peer vs peer
averag
capit deploy gear toward tuck-in pay dividend
histor repurchas share though board recent approv
buy-back program gener use deal often make technolog
acquisit mean acquir ip even dilut oper profit
manag target /revenu doubl
margin saw stronger free cash flow driven combin
higher net incom driven stronger revenu profil margin expans erp
investments/leverag ii better work capit manag erp system
manag inventory/pay level iii lower capital-expenditure reduc erp invest
trend manag note
especi bad year work capit drag vs trail five-year
averag drag new erp system improv work capit
note inventori level remain peer given structur realiti
higher inventori level model fcf/revenu margin underli
margin profil sub-optim cash convers cycl believ manag
consid drive stronger cash convers growth mean alloc capit
bio-rad global diversifi manufactur life scienc clinic
diagnost instrument consumables/reag software/servic
share own schwartz famili found compani
year grown billion sale employe
compani deriv sale diagnost end market
compani sale consumables/reag compar peer
expos us europ said decreas exposur
europ today increas exposur us
exhibit trail stock perform past five year
averag compar peer
exhibit beaten constant currenc growth target three
last five year
exhibit custom mix weight hospit lab
follow academic/govern
exhibit increas us/apac mix time
decreas eu mix
canada latin
exhibit comp show price-to-earnings premium faster expect earn growth though valuat attract ex-srt basi
multipl rel average
compani data thomson reuter morgan stanley research estim valuat methodolog risk associ price target referenc research report pleas contact client support
may contact invest repres morgan stanley research broadway attent research manag new york ny usa
exhibit trade premium yield though attract ex-srt basi
exhibit lowest tool driven erp spend
exhibit growth volatil past year
share repurchas
dividend
exhibit valuat significantli attract
consid ex-srt basi
exhibit erp invest drag look
trend improv subsid
exhibit lowest convers revenu
exhibit second-highest cash convers cycl tool
driven highest inventori day
convers cycl data number day
valuat methodolog risk
price base mid estim
median mid-larg cap tools/dent coverag given faster
growth/shar price impli base case ep in-lin
current level model organ growth acceler
ebit margin expans period
upsid risk price target includ cost save oper leverag prove
robust expect drive faster margin expans ii competitive/pr
posit defens expect clinic diagnost market iii ddpcr
penetr clinic market exce growth downsid risk
price target includ cost save materi erp implement
europ challeng lead addit invest slower margin expans ii
competitive/pr pressur intensifi clinic diagnost market iii ddpcr
growth deceler competit enter field clinic uptak slower
impair loss goodwil long-liv
incom invest
adjust incom
net incom non control interest
provis incom tax
net incom continu op
equival
purchas intang net
note payabl current matur lt debt
incom tax payabl
long-term debt net current matur
depreci amort
chang fair market valu equiti secur
divestitur product line
tax benefit share base compens
chang fair valu conting consider
impair loss goodwil long-liv asset
net cash provid oper activ
proce disposit properti plant equip
proce divestitur product line
payment acquisit long-term invest
payment purchas intang asset
payment purchas market secur invest
proce sale market secur invest
proce matur market secur invest
proce payment foreign currenc econom hedg net
net cash provid use invest activ
net payment line-of-credit arrang note payabl
payment long-term borrow
payment conting consider
purchas treasuri stock
proce issuanc common stock share-bas compens
excess tax benefit share-bas compens
net cash provid use financ activ
effect foreign exchang rate chang cash
decreas increas cash cash equival
cash equival begin period
cash equival end period
